Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dalbavancin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Dalbavancin | DRUG | Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV |
Inclusion Criteria: * 12 to 17 year old adolescents hospitalized for the treatment of bacterial infections. Exclusion Criteria: * Patients being treated with vancomycin. * Patients with liver and kidney failure. * Pregnant female subjects.
Top 20 of 28 competitors
Dalbavancin is an investigational small molecule being developed for the treatment of bacterial infections. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in humans.
Dalbavancin is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical research to evaluate the drug's potential in treating bacterial infections.
Dalbavancin is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for its safety, tolerability, and pharmacokinetics in patients with bacterial infections.
Dalbavancin has one completed clinical trial registered under NCT00678106, titled 'Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections.' This Phase 1 study enrolled 10 participants in the United States and was not randomized or double-blinded.
No alternative names for Dalbavancin have been reported in the available clinical trial information. The drug is identified solely by its generic name, Dalbavancin, in the context of its development by Pfizer for bacterial infections.